Inhibikase Therapeutics, Inc.
IKT
$1.44
$0.032.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 45.13% | -49.86% | |||
| Gross Profit | -45.13% | 49.86% | |||
| SG&A Expenses | -5.21% | 12.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.42% | -31.28% | |||
| Operating Income | -22.42% | 31.28% | |||
| Income Before Tax | -20.32% | 27.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -20.32% | 27.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.32% | 27.51% | |||
| EBIT | -22.42% | 31.28% | |||
| EBITDA | -22.48% | 31.38% | |||
| EPS Basic | -20.24% | 27.88% | |||
| Normalized Basic EPS | -25.11% | 33.49% | |||
| EPS Diluted | -20.24% | 27.88% | |||
| Normalized Diluted EPS | -25.11% | 33.49% | |||
| Average Basic Shares Outstanding | 0.05% | 0.53% | |||
| Average Diluted Shares Outstanding | 0.05% | 0.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||